Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 2739 entries
Sorted by: Best Match Show Resources per page
Exosome mediated growth effect on the non-growing pre-B acute lymphoblastic leukemia cells at low starting cell density.

American journal of translational research

Patel SJ, Darie CC, Clarkson BD.
PMID: 27725845
Am J Transl Res. 2016 Sep 15;8(9):3614-3629. eCollection 2016.

Tumors contain heterogeneous cell populations and achieve dominance by functioning as collective systems. The mechanisms underlying the aberrant growth and interactions between cells are not very well understood. The pre-B acute lymphoblastic leukemia cells we studied were obtained directly...

Cite
Patel SJ, Darie CC, Clarkson BD. Exosome mediated growth effect on the non-growing pre-B acute lymphoblastic leukemia cells at low starting cell density. Am J Transl Res. 2016;8(9):3614-3629
Patel, S. J., Darie, C. C., & Clarkson, B. D. (2016). Exosome mediated growth effect on the non-growing pre-B acute lymphoblastic leukemia cells at low starting cell density. American journal of translational research, 8(9), 3614-3629.
Patel, Sapan J, et al. "Exosome mediated growth effect on the non-growing pre-B acute lymphoblastic leukemia cells at low starting cell density." American journal of translational research vol. 8,9 (2016): 3614-3629.
Patel SJ, Darie CC, Clarkson BD. Exosome mediated growth effect on the non-growing pre-B acute lymphoblastic leukemia cells at low starting cell density. Am J Transl Res. 2016 Sep 15;8(9):3614-3629. eCollection 2016. PMID: 27725845; PMCID: PMC5040663.
Copy Download .nbib Format: NLM
Multimodality functional imaging using DW-MRI and .

World journal of radiology

Aramburu Núñez D, Lopez Medina A, Mera Iglesias M, Salvador Gomez F, Dave A, Hatzoglou V, Paudyal R, Calzado A, Deasy JO, Shukla-Dave A, Muñoz VM.
PMID: 28144403
World J Radiol. 2017 Jan 28;9(1):17-26. doi: 10.4329/wjr.v9.i1.17.

AIM: To noninvasively investigate tumor cellularity measured using diffusion-weighted magnetic resonance imaging (DW-MRI) and glucose metabolism measured by METHODS: In this prospective study, 6 HPV- HNSCC patients underwent a total of 34 multimodality imaging examinations DW-MRI at 1.5 T...

Cite
Aramburu Núñez D, Lopez Medina A, Mera Iglesias M, et al. Multimodality functional imaging using DW-MRI and . World J Radiol. 2017;9(1):17-26doi: 10.4329/wjr.v9.i1.17.
Aramburu Núñez, D., Lopez Medina, A., Mera Iglesias, M., Salvador Gomez, F., Dave, A., Hatzoglou, V., Paudyal, R., Calzado, A., Deasy, J. O., Shukla-Dave, A., & Muñoz, V. M. (2017). Multimodality functional imaging using DW-MRI and . World journal of radiology, 9(1), 17-26. https://doi.org/10.4329/wjr.v9.i1.17
Aramburu Núñez, David, et al. "Multimodality functional imaging using DW-MRI and ." World journal of radiology vol. 9,1 (2017): 17-26. doi: https://doi.org/10.4329/wjr.v9.i1.17
Aramburu Núñez D, Lopez Medina A, Mera Iglesias M, Salvador Gomez F, Dave A, Hatzoglou V, Paudyal R, Calzado A, Deasy JO, Shukla-Dave A, Muñoz VM. Multimodality functional imaging using DW-MRI and . World J Radiol. 2017 Jan 28;9(1):17-26. doi: 10.4329/wjr.v9.i1.17. PMID: 28144403; PMCID: PMC5241537.
Copy Download .nbib Format: NLM
Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis.

ChemistryOpen

Zeglis BM, Emmetiere F, Pillarsetty N, Weissleder R, Lewis JS, Reiner T.
PMID: 24808990
ChemistryOpen. 2014 Apr;3(2):48-53. doi: 10.1002/open.201402000. Epub 2014 Apr 06.

The need for post-synthetic modifications and reactive prosthetic groups has long been a limiting factor in the synthesis and study of peptidic and peptidomimetic imaging agents. In this regard, the application of biologically and chemically orthogonal reactions to the...

Cite
Zeglis BM, Emmetiere F, Pillarsetty N, et al. Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis. ChemistryOpen. 2014;3(2):48-53doi: 10.1002/open.201402000.
Zeglis, B. M., Emmetiere, F., Pillarsetty, N., Weissleder, R., Lewis, J. S., & Reiner, T. (2014). Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis. ChemistryOpen, 3(2), 48-53. https://doi.org/10.1002/open.201402000
Zeglis, Brian M, et al. "Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis." ChemistryOpen vol. 3,2 (2014): 48-53. doi: https://doi.org/10.1002/open.201402000
Zeglis BM, Emmetiere F, Pillarsetty N, Weissleder R, Lewis JS, Reiner T. Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis. ChemistryOpen. 2014 Apr;3(2):48-53. doi: 10.1002/open.201402000. Epub 2014 Apr 06. PMID: 24808990; PMCID: PMC4000166.
Copy Download .nbib Format: NLM
Nuclear positioning in muscle development and disease.

Frontiers in physiology

Folker ES, Baylies MK.
PMID: 24376424
Front Physiol. 2013 Dec 12;4:363. doi: 10.3389/fphys.2013.00363.

Muscle disease as a group is characterized by muscle weakness, muscle loss, and impaired muscle function. Although the phenotype is the same, the underlying cellular pathologies, and the molecular causes of these pathologies, are diverse. One common feature of...

Cite
Folker ES, Baylies MK. Nuclear positioning in muscle development and disease. Front Physiol. 2013;4:363doi: 10.3389/fphys.2013.00363.
Folker, E. S., & Baylies, M. K. (2013). Nuclear positioning in muscle development and disease. Frontiers in physiology, 4363. https://doi.org/10.3389/fphys.2013.00363
Folker, Eric S, and Baylies, Mary K. "Nuclear positioning in muscle development and disease." Frontiers in physiology vol. 4 (2013): 363. doi: https://doi.org/10.3389/fphys.2013.00363
Folker ES, Baylies MK. Nuclear positioning in muscle development and disease. Front Physiol. 2013 Dec 12;4:363. doi: 10.3389/fphys.2013.00363. PMID: 24376424; PMCID: PMC3859928.
Copy Download .nbib Format: NLM
Opportunistic infections in patients treated with immunotherapy for cancer.

Journal for immunotherapy of cancer

Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA.
PMID: 24991413
J Immunother Cancer. 2014 Jun 18;2:19. doi: 10.1186/2051-1426-2-19. eCollection 2014.

Immunomodulatory antibodies that enhance the immune system to fight cancer are revolutionizing the treatment of patients with an expanding variety of malignancies. There is a unique spectrum of side effects associated with immunomodulatory antibodies, termed immune-related adverse events (irAEs),...

Cite
Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014;2:19doi: 10.1186/2051-1426-2-19.
Kyi, C., Hellmann, M. D., Wolchok, J. D., Chapman, P. B., & Postow, M. A. (2014). Opportunistic infections in patients treated with immunotherapy for cancer. Journal for immunotherapy of cancer, 219. https://doi.org/10.1186/2051-1426-2-19
Kyi, Chrisann, et al. "Opportunistic infections in patients treated with immunotherapy for cancer." Journal for immunotherapy of cancer vol. 2 (2014): 19. doi: https://doi.org/10.1186/2051-1426-2-19
Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014 Jun 18;2:19. doi: 10.1186/2051-1426-2-19. eCollection 2014. PMID: 24991413; PMCID: PMC4079190.
Copy Download .nbib Format: NLM
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.

Sarcoma

Dickson MA, D'Adamo DR, Keohan ML, D'Angelo SP, Carvajal RD, Gounder MM, Maki RG, Qin LX, Lefkowitz RA, McKennon OR, Hirst CM, Schwartz GK, Tap WD.
PMID: 26074722
Sarcoma. 2015;2015:532478. doi: 10.1155/2015/532478. Epub 2015 May 14.

Gemcitabine (G) and docetaxel (D) are commonly used to treat recurrent/metastatic soft tissue sarcoma. This study tested the hypothesis that outcomes would be improved by addition of bevacizumab (B). The initial design was randomized double-blind trial of G +...

Cite
Dickson MA, D'Adamo DR, Keohan ML, et al. Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma. 2015;2015:532478doi: 10.1155/2015/532478.
Dickson, M. A., D'Adamo, D. R., Keohan, M. L., D'Angelo, S. P., Carvajal, R. D., Gounder, M. M., Maki, R. G., Qin, L. X., Lefkowitz, R. A., McKennon, O. R., Hirst, C. M., Schwartz, G. K., & Tap, W. D. (2015). Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma, 2015532478. https://doi.org/10.1155/2015/532478
Dickson, Mark A, et al. "Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma." Sarcoma vol. 2015 (2015): 532478. doi: https://doi.org/10.1155/2015/532478
Dickson MA, D'Adamo DR, Keohan ML, D'Angelo SP, Carvajal RD, Gounder MM, Maki RG, Qin LX, Lefkowitz RA, McKennon OR, Hirst CM, Schwartz GK, Tap WD. Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma. 2015;2015:532478. doi: 10.1155/2015/532478. Epub 2015 May 14. PMID: 26074722; PMCID: PMC4446476.
Copy Download .nbib Format: NLM
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent.

Experimental hematology & oncology

Mondello P, Pitini V, Barresi V, Brea EJ, Di Mirto C, Arrigo C, Cuzzocrea S, Mian M.
PMID: 26740908
Exp Hematol Oncol. 2016 Jan 06;5:1. doi: 10.1186/s40164-015-0030-1. eCollection 2015.

BACKGROUND: Although the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) has been improved by the addition of rituximab to standard chemotherapy, almost one-third fails or relapses after first line treatment. The presence of monoclonal gammopathy...

Cite
Mondello P, Pitini V, Barresi V, et al. Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. Exp Hematol Oncol. 2016;5:1doi: 10.1186/s40164-015-0030-1.
Mondello, P., Pitini, V., Barresi, V., Brea, E. J., Di Mirto, C., Arrigo, C., Cuzzocrea, S., & Mian, M. (2015). Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. Experimental hematology & oncology, 51. https://doi.org/10.1186/s40164-015-0030-1
Mondello, Patrizia, et al. "Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent." Experimental hematology & oncology vol. 5 (2015): 1. doi: https://doi.org/10.1186/s40164-015-0030-1
Mondello P, Pitini V, Barresi V, Brea EJ, Di Mirto C, Arrigo C, Cuzzocrea S, Mian M. Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. Exp Hematol Oncol. 2016 Jan 06;5:1. doi: 10.1186/s40164-015-0030-1. eCollection 2015. PMID: 26740908; PMCID: PMC4702294.
Copy Download .nbib Format: NLM
Options for Breast Reconstruction after Mastectomy for Carcinoma of the Breast: An Observational Experience at MSKCC, New York under UICC Fellowship.

Indian journal of surgical oncology

Das PK, Cordeiro PG.
PMID: 27065656
Indian J Surg Oncol. 2015 Dec;6(4):327-9. doi: 10.1007/s13193-015-0406-z. Epub 2015 Apr 24.

The first Author went to visit The Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA on UICC ICRETT Fellowship to observe as many clinical situations of options of breast reconstruction after mastectomy for carcinoma breast during a period...

Cite
Das PK, Cordeiro PG. Options for Breast Reconstruction after Mastectomy for Carcinoma of the Breast: An Observational Experience at MSKCC, New York under UICC Fellowship. Indian J Surg Oncol. 2015;6(4):327-9doi: 10.1007/s13193-015-0406-z.
Das, P. K., & Cordeiro, P. G. (2015). Options for Breast Reconstruction after Mastectomy for Carcinoma of the Breast: An Observational Experience at MSKCC, New York under UICC Fellowship. Indian journal of surgical oncology, 6(4), 327-9. https://doi.org/10.1007/s13193-015-0406-z
Das, Prafulla Kumar, and Cordeiro, Peter G. "Options for Breast Reconstruction after Mastectomy for Carcinoma of the Breast: An Observational Experience at MSKCC, New York under UICC Fellowship." Indian journal of surgical oncology vol. 6,4 (2015): 327-9. doi: https://doi.org/10.1007/s13193-015-0406-z
Das PK, Cordeiro PG. Options for Breast Reconstruction after Mastectomy for Carcinoma of the Breast: An Observational Experience at MSKCC, New York under UICC Fellowship. Indian J Surg Oncol. 2015 Dec;6(4):327-9. doi: 10.1007/s13193-015-0406-z. Epub 2015 Apr 24. PMID: 27065656; PMCID: PMC4809848.
Copy Download .nbib Format: NLM
[No title available]

Chemical science

Walkowicz WE, Fernández-Tejada A, George C, Corzana F, Jiménez-Barbero J, Ragupathi G, Tan DS, Gin DY.
PMID: 27014435
Chem Sci. 2016 Mar;7(3):2371-2380. doi: 10.1039/C5SC02978C. Epub 2016 Jan 15.

Immunological adjuvants such as the saponin natural product QS-21 help stimulate the immune response to co-administered antigens and have become increasingly important in the development of prophylactic and therapeutic vaccines. However, clinical use of QS21 is encumbered by chemical...

Cite
Walkowicz WE, Fernández-Tejada A, George C, et al. . Chem Sci. 2016;7(3):2371-2380doi: 10.1039/C5SC02978C.
Walkowicz, W. E., Fernández-Tejada, A., George, C., Corzana, F., Jiménez-Barbero, J., Ragupathi, G., Tan, D. S., & Gin, D. Y. (2016). . Chemical science, 7(3), 2371-2380. https://doi.org/10.1039/C5SC02978C
Walkowicz, William E, et al. "." Chemical science vol. 7,3 (2016): 2371-2380. doi: https://doi.org/10.1039/C5SC02978C
Walkowicz WE, Fernández-Tejada A, George C, Corzana F, Jiménez-Barbero J, Ragupathi G, Tan DS, Gin DY. . Chem Sci. 2016 Mar;7(3):2371-2380. doi: 10.1039/C5SC02978C. Epub 2016 Jan 15. PMID: 27014435; PMCID: PMC4800320.
Copy Download .nbib Format: NLM
Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma.

PloS one

Correa-Gallego C, Maddalo D, Doussot A, Kemeny N, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Betel D, Klimstra D, Jarnagin WR, Ventura A.
PMID: 27685844
PLoS One. 2016 Sep 29;11(9):e0163699. doi: 10.1371/journal.pone.0163699. eCollection 2016.

BACKGROUND: MicroRNAs (miRNAs) are potential biomarkers in various malignancies. We aim to characterize miRNA expression in intrahepatic cholangiocarcinoma (ICC) and identify circulating plasma miRNAs with potential diagnostic and prognostic utility.METHODS: Using deep-sequencing techniques, miRNA expression between tumor samples and...

Cite
Correa-Gallego C, Maddalo D, Doussot A, et al. Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. PLoS One. 2016;11(9):e0163699doi: 10.1371/journal.pone.0163699.
Correa-Gallego, C., Maddalo, D., Doussot, A., Kemeny, N., Kingham, T. P., Allen, P. J., D'Angelica, M. I., DeMatteo, R. P., Betel, D., Klimstra, D., Jarnagin, W. R., & Ventura, A. (2016). Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. PloS one, 11(9), e0163699. https://doi.org/10.1371/journal.pone.0163699
Correa-Gallego, Camilo, et al. "Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma." PloS one vol. 11,9 (2016): e0163699. doi: https://doi.org/10.1371/journal.pone.0163699
Correa-Gallego C, Maddalo D, Doussot A, Kemeny N, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Betel D, Klimstra D, Jarnagin WR, Ventura A. Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. PLoS One. 2016 Sep 29;11(9):e0163699. doi: 10.1371/journal.pone.0163699. eCollection 2016. PMID: 27685844; PMCID: PMC5042503.
Copy Download .nbib Format: NLM
Ablation of the sacroiliac joint using MR-guided high intensity focused ultrasound: a preliminary experiment in a swine model.

Journal of therapeutic ultrasound

Kaye EA, Maybody M, Monette S, Solomon SB, Gulati A.
PMID: 28652915
J Ther Ultrasound. 2017 Jun 26;5:17. doi: 10.1186/s40349-017-0095-x. eCollection 2017.

BACKGROUND: Dysfunction of the Sacroiliac Joint (SIJ) is one of the key sources of low back pain. For prolonged pain relief, some patients undergo fluoroscopic guided radio-frequency (RF) ablation of SIJ, during which a number of RF probes are...

Cite
Kaye EA, Maybody M, Monette S, et al. Ablation of the sacroiliac joint using MR-guided high intensity focused ultrasound: a preliminary experiment in a swine model. J Ther Ultrasound. 2017;5:17doi: 10.1186/s40349-017-0095-x.
Kaye, E. A., Maybody, M., Monette, S., Solomon, S. B., & Gulati, A. (2017). Ablation of the sacroiliac joint using MR-guided high intensity focused ultrasound: a preliminary experiment in a swine model. Journal of therapeutic ultrasound, 517. https://doi.org/10.1186/s40349-017-0095-x
Kaye, Elena A, et al. "Ablation of the sacroiliac joint using MR-guided high intensity focused ultrasound: a preliminary experiment in a swine model." Journal of therapeutic ultrasound vol. 5 (2017): 17. doi: https://doi.org/10.1186/s40349-017-0095-x
Kaye EA, Maybody M, Monette S, Solomon SB, Gulati A. Ablation of the sacroiliac joint using MR-guided high intensity focused ultrasound: a preliminary experiment in a swine model. J Ther Ultrasound. 2017 Jun 26;5:17. doi: 10.1186/s40349-017-0095-x. eCollection 2017. PMID: 28652915; PMCID: PMC5483839.
Copy Download .nbib Format: NLM
Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy.

PloS one

Miles LA, Brennen WN, Rudin CM, Poirier JT.
PMID: 26287921
PLoS One. 2015 Aug 19;10(8):e0136480. doi: 10.1371/journal.pone.0136480. eCollection 2015.

No abstract available.

Cite
Miles LA, Brennen WN, Rudin CM, et al. Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy. PLoS One. 2015;10(8):e0136480doi: 10.1371/journal.pone.0136480.
Miles, L. A., Brennen, W. N., Rudin, C. M., & Poirier, J. T. (2015). Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy. PloS one, 10(8), e0136480. https://doi.org/10.1371/journal.pone.0136480
Miles, Linde A, et al. "Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy." PloS one vol. 10,8 (2015): e0136480. doi: https://doi.org/10.1371/journal.pone.0136480
Miles LA, Brennen WN, Rudin CM, Poirier JT. Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy. PLoS One. 2015 Aug 19;10(8):e0136480. doi: 10.1371/journal.pone.0136480. eCollection 2015. PMID: 26287921; PMCID: PMC4546053.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 2739 entries